Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a single-centre, open-label Phase II study of the investigational drugs binimetinib
and encorafenib that will be taken my mouth (orally) daily in adult patient with advanced
and/or metastatic solid tumors for which no other standard therapy is available. The main
purpose is to evaluate the objective response rate (ORR) of the study drugs in the growth of
the cancer in patients with class 2 and 3 BRAF mutations.